VAXIMM AG

VAXIMM AG

Developing innovative oral T-cell immunotherapies to treat cancer patients

Founded 2008

Basel, Switzerland 4 employees Grant Total: $7.80M Biotechnology, Health and Wellness +1

VAXIMM AG is a biotech startup that aims to revolutionize cancer treatment through the development of innovative oral T-cell immunotherapies. Founded in 2008 and headquartered in Switzerland, VAXIMM AG has made significant strides in its field. The company's lead product candidate, oral VXM01, has shown promise in activating killer cells targeting tumor-specific vasculature and immune-suppressive cells in clinical trials, particularly for brain cancer patients. Additionally, VAXIMM AG has entered into strategic partnerships with key players in the industry such as Merck KGaA, Darmstadt, Germany and China Medical System Holdings (CMS). This collaboration has enabled the company to further its presence in the Asian market, granting CMS full rights in China and other Asian countries (excluding Japan) to VAXIMM’s existing programs. With its subsidiary, VAXIMM GmbH, located in Mannheim, Germany, the company is actively engaged in advancing its innovative oral T-cell immunotherapy platform. VAXIMM AG's development of oral T-cell immunotherapies demonstrates its commitment to pioneering solutions for cancer patients, making it a compelling investment opportunity within the biotechnology sector.

Funding Stage	Amount	Investors	Lead Investors	Date
Grant	Undisclosed	-		02 Oct 2012
Venture Round	Fr.7.80M	4	Sunstone Capital, BB Biotech Ventures +2	12 Jan 2011

Funding Stage

Amount

Investors

Lead Investors

Date

Grant

Undisclosed

02 Oct 2012

Venture Round

Fr.7.80M

Sunstone Capital, BB Biotech Ventures +2

12 Jan 2011

FAQ About VAXIMM AG

Developing innovative oral T-cell immunotherapies to treat cancer patients

VAXIMM AG was founded in 2008.

VAXIMM AG is headquartered in Basel, Switzerland.

VAXIMM AG operates in Biotechnology, Health and Wellness and Platforms. Its work centres on Biotech, Cancer treatment, Immunotherapy and Oral T-cell immunotherapies.

VAXIMM AG has approximately 4 employees.

VAXIMM AG has completed 2 funding rounds, raising a total of $7.80M. The latest funding stage is Grant.

Top alternatives and competitors to VAXIMM AG include Jounce Therapeutics, Inc., Eureka Therapeutics, Inc, Imvax, Inc., Korecyte Bio, Boostimmune. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

VAXIMM AG and Jounce Therapeutics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About VAXIMM AG

Funding Rounds & Investors (2)

VAXIMM AG Alternatives & Competitors

FAQ About VAXIMM AG